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in the CV group (p<0.01). There was no annulus rupture, coronary
obstruction or periprocedural death. The rate of postprocedural non-
disabling or disabling stroke was similar. There was a statistical sig-
niﬁcance in the rate of paravalvular aortic regurgitation by
postprocedural echocardiography with moderate or severe aortic
regurgitation of 20% in the CV population versus 1% in the ES3 pop-
ulation (p<0.01). Numbers for mild regurgitation were 43 % vs. 31 %
(p¼0.22), none or trace 37% vs. 68% (p<0.01), respectively. Life
threatening bleeding according to VARC was similar (CV 1% vs. ES3
0%, p¼0.37). There was a statistical signiﬁcant lower rate of post-
procedural new pacemaker implantation for the ES3 with 15% versus
31% for the CV (p<0.01).
CONCLUSIONS Transfemoral TAVI with the new ES3 compared with
the CoreValve was associated with a statistical signiﬁcant lower rate of
moderate or severe aortic regurgitation, signiﬁcant lower need for
pacemaker implantation and a signiﬁcant higher rate of device suc-
cess according to VARC.
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BACKGROUND Moderate and severe aortic regurgitation after TAVI
with the Edwards Sapien XT (EXT) valve were associated with a higher
acute and long-term mortality in the Partner trial. The second gen-
eration Edwards Sapien S3 (ES3) valve has an outer skirt at the distal
part of the valve, designed to reduce paravalvular aortic regurgitation.
We compared outcome of patients after TAVI with the EXT and ES3 in
200 patients.
METHODS The ﬁrst 100 consecutive patients treated with the ES3
were compared with the last 100 consecutive patients treated with the
EXT valve (Clinical Trial Registration: NCT02162069). Mean STS-Score
was 118%. Postprocedural paravalvular regurgitation, rate of pace-
maker implantation and device success were analyzed according to
VARC criteria. Sizing was based on multislice computer tomography
performed with a 256 Philips Brilliance iCT scanner. Measurements of
aortic annulus, left ventricular outﬂow tract (LVOT) and distance from
annulus to coronary ostia were measured with a dedicated software
(3mensio Structural Heart,version 7.0).
RESULTS Baseline characteristics were similar between the EXT and
ES3 population Also the following computer tomography acquired
parameters did not differ signiﬁcantly between the EXT and ES3
population: aortic annulus area derived diameter 24.42.3 vs.
24.72.4 mm (p¼0.37), aortic annulus perimeter derived diameter
25.72.4 vs. 25.42.5 mm (p¼0.45), aortic annulus area 46799 vs.
48396 mm2 (p¼0.25), LVOT area derived diameter 24.32.8 vs.
24.62.6 mm (p¼0.48), LVOT perimeter derived diameter 25.52.9 vs.
25.62.6 mm (p¼0.94), LVOT area 471108 vs. 480101 mm2
(p¼0.52), heavy calciﬁcation of the aortic annulus (Rosenhek Grade
IV) 94% vs. 100% (p¼0.67) or heavy calciﬁcation of the LVOT 32% vs.
33% (p¼0.88). Size of the EXT was 23mm in 31%, 26mm in 44%, 29mm
in 25%. Numbers for ES3 were 29%, 50% and 21%, respectively. Post
dilation was done in 1% after EXT implantation and none after ES3
implantation. Rate of device success according to VARC was high in
both groups (p¼0.77). There was one intraprocedural death in the EXT
group, none in the ES3 population. There was no annulus rupture or
coronary obstruction. The rate of postprocedural stroke was similar
(p¼0.52). There was a higher rate of mild to severe aortic regurgitation
in postprocedural echocardiography of 42% in the EXT population
versus 32% in the ES3 group (p¼0.12). No severe aortic regurgitation
was found in neither group. Life threatening bleeding according to
VARC was signiﬁcantly lower with ES3 versus EXT (0% vs. 9%,
p<0.01). The need for permanent pacemaker implantation was higher
for EXT with 22% versus 15% for ES3 (p¼0.20).
CONCLUSIONS Transfemoral TAVI with the second generation ES3
compared with the EXT resulted in a lower rate of aortic regurgitation
(mild-severe), lower need for pacemaker implantation and a signiﬁ-
cantly lower bleeding risk.
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BACKGROUND Transfemoral transcatheter aortic valve replacement
(TF TAVR) can be performed under general anesthesia (GA) or mod-
erate sedation (MS). Despite observational studies suggesting a
shorter length of stay (LOS), shorter procedural time and a similar
mortality rate with MS, only 5% of patients undergoing TF TAVR in
the United States are done with this type of anesthesia. We reviewed
the implementation of a MS for TF TAVR protocol at a single institu-
tion with no previous experience with this technique.
METHODS Patients with severe obstructive sleep apnea (OSA), likely
difﬁcult intubation, inability to tolerate supine position due to
musculoskeletal disease, or barriers to communication including
altered mental status were performed under GA with intraoperative
transesophageal echocardiography. All others received MS with an
ilioinguinal nerve block and intraoperative transthoracic echocardi-
ography. The MS for TF TAVR protocol was implemented on October
9th, 2014. The records of patients undergoing TF TAVR 6 months
before and after protocol implementation were retrospectively
reviewed.
RESULTS In the pre protocol group 33 patients underwent TF TAVR
under GA and no patients received MS. In the post protocol group, 97
underwent TF TAVR, 81 (83.5%) of which received MS. OSA was the
most common reason for GA (N¼10, 62.5%). Conversion from MS to GA
occurred in 2 cases (2.5%) due to procedural complications, of which 1
resulted in death. All other cases involving MS were tolerated well and
there were no anesthesia related complications. Post procedural LOS
(3.2 days vs. 5.0 days, p¼0.002) and procedure time (144.0 minutes vs.
96.1 minutes, p<0.001) were both signiﬁcantly shorter in post proto-
col group. The post protocol group was also signiﬁcantly less likely to
require a skilled nursing facility upon discharge (24.2% vs. 8.2%,
p¼0.027). In hospital mortality was similar between groups (N¼2 6.1%
vs. N¼3, 3.1%, p¼0.601).Pre-Protocol Post-Protocol p-ValueN 33 97Moderate Sedation: N
(%)0 (0) 81 (83.5)Post Procedure Length
of Stay: Days5.0  3.2 (4) 3.2 2.8 (3) 0.002Procedure Time:
Minutes144.0  54.9 (129) 96.1  31.3 (88) <0.001Skilled Nursing Facility
on Discharge: N (%)8 (24.2) 8 (8.2) 0.027In Hospital Mortality:
N (%)2 (6.1) 3 (3.1) 0.601NOTE: Values are in numbers, means  SD (medians), or numbers (percentages).
CONCLUSIONS The MS for TF TAVR protocol appears safe and can be
rapidly implemented at institutions with no previous MS experience.
This technique is feasible in the majority of patient undergoing TF
TAVR. Post procedural LOS and procedural time are multifactorial, but
this data further suggests MS may be beneﬁcial in select patients.
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